Todd Sone is a General Partner at aMoon, where he brings 20 years of healthcare investment experience as a sell side analyst, LP and buy side investor to co-lead our late-stage team. As a student, Todd worked part-time in his father’s pharmaceutical warehouse, which inspired him to pursue a career in the healthcare industry. His greatest passion is working with entrepreneurs to bring transformative products to market.
Todd sits on the boards of Ayala Pharmaceuticals (AYLA), Scipher Medicine, Biolojic Design, MOBILion, Smart Medical Systems, our stealth mode genomics company and Theranica. Before joining aMoon, Todd was a Managing Director at Signet Healthcare Partners, an investment fund that provides growth capital to commercial-stage life-science companies. He co-led the investment in Claris Lifesciences (sold to Baxter), and served on the boards of Arbor Pharmaceuticals (sold to KKR) and Apicore (sold to Medicure). Prior to Signet, Todd served as an Investment Director at Joddes, a family office with interests in numerous life science companies, including Medicom, Paladin Labs, and Oral Science. Earlier in his career, Todd was an equity analyst at Morgan Stanley and Goldman Sachs in New York, covering the US pharmaceutical sector.
Todd received a Bachelor of Commerce with High Distinction from the University of Toronto, and an MBA from The Wharton School at the University of Pennsylvania with concentrations in healthcare management and finance.